Mantle cell lymphoma (MCL)

Mantle cell lymphoma (MCL) is diagnosed from a tissue sample (a biopsy), most often a swollen lymph node. European guidelines prefer removing a whole node when possible. A pathologist looks for high levels of a protein called cyclin D1, or for the gene change behind it: a swap between chromosomes 11 and 14, written t(11;14). The same guidelines advise that expert lymphoma pathologists (hematopathologists) review the diagnosis.

More lab tests show how the lymphoma is likely to behave. A protein called SOX11 helps separate the usual form from a less common form that mainly involves the blood and bone marrow and often enlarges the spleen. A Ki-67 stain shows how many cells are dividing. A TP53 gene test, advised at diagnosis in European guidelines, looks for a change linked to harder-to-treat disease.

To see where the lymphoma is, teams usually order CT scans, often a PET-CT, and a bone marrow sample. The marrow is checked with flow cytometry, a test that sorts cells by the markers on their surface. MCL can hide in the gut. So when it seems to be at an early, limited stage, European guidelines recommend an endoscopy of the stomach and bowel as well.

Selected asymptomatic patients with indolent disease can be monitored. Most symptomatic patients receive systemic treatment, which may include an anti-CD20 antibody, chemotherapy and/or a BTK inhibitor according to the clinical setting.

High-dose chemotherapy with autologous stem cell rescue has been used after initial treatment for eligible patients. Modern BTK-inhibitor-containing regimens and response assessment are changing this role, so first-remission autologous transplantation is no longer an automatic step for every fit patient.

At relapse, BTK inhibitors, CAR-T therapy, other targeted combinations and clinical trials are important options. Allogeneic transplantation is considered for selected patients, for example after failure of or lack of access to other effective approaches. Drug and cellular treatment selection depends on prior exposure and disease biology.

MCL is usually not cured with standard treatment, because it tends to come back. But many people live with it for years, moving between treatment, remission and monitoring. The National Cancer Institute notes that many older people stay in remission for the rest of their lives. Outlook has improved a great deal over the past two decades. Rituximab, high-dose cytarabine and, for younger adults, the BTK inhibitor ibrutinib were added to first treatment.

Several things shape outlook. Age and other health problems matter. So does the biology of the lymphoma: a high Ki-67 score, blastoid or pleomorphic cells (larger, faster-growing cells) and TP53 gene changes point to a harder course. Timing matters too. In a study of 564 people in Finland and Spain, MCL that got worse within two years of diagnosis was a strong sign of a harder road ahead.

When MCL comes back, newer options such as other BTK inhibitors and CAR-T therapy can bring new remissions. The numbers below come from groups of people treated in the past, so they describe groups, not any one person.